Results

Total Results: 222 records

Showing results for "disorder".

  1. srdr.ahrq.gov/projects/1165
    May 29, 2019 - (DD)—major depressive disorder (MDD), persistent depressive disorder (PDD, previously termed dysthymia … How do the benefits and harms vary by subpopulation (e.g., patient characteristics, disorder characteristics … How do the benefits and harms vary by subpopulation (e.g., patient characteristics, disorder characteristics … How do the benefits and harms vary by subpopulation (e.g., patient characteristics, disorder characteristics … Belmaker 2006 Paroxetine treatment in children and adolescents with major depressive disorder
  2. srdr.ahrq.gov/projects/1165/studies/186915
    January 01, 2006 - international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder
  3. srdr.ahrq.gov/projects/1165/studies/186944
    January 01, 2018 - Description Predictors and moderators of relapse in children and adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … Title Predictors and moderators of relapse in children and adolescents with major depressive disorder
  4. srdr.ahrq.gov/projects/1165/studies/186913
    January 01, 2006 - Title and Description Paroxetine treatment in children and adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … Title Data Title Paroxetine treatment in children and adolescents with major depressive disorder
  5. srdr.ahrq.gov/projects/1165/studies/186939
    January 01, 1992 - double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder
  6. srdr.ahrq.gov/projects/1165/studies/186945
    January 01, 2018 - Desvenlafaxine versus placebo in a fluoxetine-referenced study of children and adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … Desvenlafaxine versus placebo in a fluoxetine-referenced study of children and adolescents with major depressive disorder
  7. srdr.ahrq.gov/projects/1165/studies/186943
    January 01, 2018 - double-blind, randomized, placebo-controlled study of vilazodone in adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … double-blind, randomized, placebo-controlled study of vilazodone in adolescents with major depressive disorder
  8. srdr.ahrq.gov/projects/1165/studies/186954
    January 01, 2018 - Desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … Desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder
  9. srdr.ahrq.gov/projects/1165/studies/186893
    January 01, 2014 - efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder
  10. srdr.ahrq.gov/projects/1165/studies/186894
    January 01, 2014 - efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder
  11. srdr.ahrq.gov/projects/1165/studies/186941
    January 01, 2009 - Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder … benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder … Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder
  12. srdr.ahrq.gov/projects/1324/studies/192174
    January 01, 2019 - Title and Description Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder … Title Data Title Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder … Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder: Groundwork for a Publicly
  13. srdr.ahrq.gov/projects/1626/studies/193192
    January 01, 2003 - Preview Study Title and Description Health care costs associated with posttraumatic stress disorder … Title Data Title Health care costs associated with posttraumatic stress disorder
  14. srdr.ahrq.gov/projects/1596/studies/192276
    January 01, 2017 - naloxone reduce morbidity or mortality, or improve other health outcomes in persons with opioid use disorder … What are the harms of naloxone in persons with opioid use disorder or misuse?
  15. srdr.ahrq.gov/projects/1596/studies/192277
    January 01, 2016 - naloxone reduce morbidity or mortality, or improve other health outcomes in persons with opioid use disorder … What are the harms of naloxone in persons with opioid use disorder or misuse?
  16. srdr.ahrq.gov/projects/1596/studies/192268
    January 01, 2001 - Description A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder … A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder
  17. srdr.ahrq.gov/projects/1596/studies/192269
    January 01, 2001 - Description Clinical profile of participants in a brief intervention program for cannabis use disorder … Title Clinical profile of participants in a brief intervention program for cannabis use disorder
  18. srdr.ahrq.gov/projects/1165/studies/186921
    January 01, 2004 - study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder … study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder
  19. srdr.ahrq.gov/projects/1165/studies/186948
    January 01, 2012 - and bupropion for the treatment of problematic on-line game play in adolescents with major depressive disorder … and bupropion for the treatment of problematic on-line game play in adolescents with major depressive disorder
  20. srdr.ahrq.gov/projects/1671/studies/196089
    January 01, 1995 - nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1) misuse, opioid use disorder … acute treatment, what is the accuracy of instruments for predicting risk of opioid misuse, opioid use disorder … treatment, what is the effectiveness of instruments for predicting risk of opioid misuse, opioid use disorder

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

You selected to view results for the following site: